Genetic heterogeneity of variable number tandem repeats in thymidylate synthase gene in colorectal cancer patients

International Journal of Biological Markers

Volumn 19, Issue 4, 2004, Pages 332-336

  Agostini, Marco ^a   Pucciarelli, S ^a   Calandra, P ^a   Villani, F ^a   Lise, M ^a   Nitti, D ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Colorectal cancer; Microsatellite instability; Thymidylate synthase; Variable number tandem repeats

Indexed keywords

DNA; GENE PRODUCT; MICROSATELLITE DNA; NUCLEOTIDE; REPETITIVE DNA; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER SURGERY; CHROMOSOME 18P; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; DINUCLEOTIDE REPEAT; DNA DETERMINATION; ENHANCER REGION; GENE AMPLIFICATION; GENE FUNCTION; GENE LOCUS; GENE MAPPING; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RECOMBINATION; GENETIC STABILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; HYPOTHESIS; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PROMOTER REGION; TRINUCLEOTIDE REPEAT; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 12344292612     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.3961     Document Type: Article

References (22)

1. Boland R. Genetic pathways to colorectal cancer. Hosp Pract (Off Ed) 1997; 10: 79-96.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-9.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
4. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-60.
5. Jessup JM, Bleday R, Busse P, et al. Conservative management of rectal carcinoma: the efficacy of a multimodality approach. Sem Surg Oncol 1993; 9: 39-45.
6. Tsao J L, Yatabe Y, Salovaara R, et al. Genetic reconstruction of individual colorectal tumor histories. Proc Natl Acad Sci 2000; 97: 1236-41.
7. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Ann Rev Med 2003; 54: 437-52.
8. Grem JL. Fluoropyrimidines. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: Principles and practice. Philadelphia: Lippincott-Raven, 1996.
9. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-7.
10. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
11. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
12. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997; 57: 4749-56.
13. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85: 827-30.
14. Van Triest B, Peters GJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999; 57: 179-94.
15. Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19: 1779-86.
16. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 2002; 17: 46-9.
17. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989; 244: 207-11.
18. Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19: 383-6.
19. Kinzler KW, Vogelstein B, Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
20. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
21. Loeb LA. Mutator phenotype may be required for multi-stage carcinogenesis. Cancer Res 1991; 51: 3075-9.
22. Sprent J, Tough DF. Lymphocyte life-span and memory. Science 1994; 265: 1395-400.